ARCHIVES

Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

In Brief: Sabin Leaves Frederick For So. Carolina; Georgia Worried Over Missing Out On Comprehensive Center

October 11, 1974

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

CMS Final Rule Imposes 6 Percent Cut On Physician Fees Over Four Years

November 6, 2009

NCI Still Trying To Broaden Group B Drug Distribution

May 5, 1978

Two Phase II Studies of Ibrutinib Deliver High Response Rates

December 27, 2013